Skip to main content
Clinical Trials/NCT01559259
NCT01559259
Completed
Phase 2

EVALUATION OF THE EFFICACY OF NOVEL IBUPROFEN ACETAMINOPHEN COMBINATION FORMULATIONS IN THE TREATMENT OF POST-SURGICAL DENTAL PAIN

Pfizer1 site in 1 country394 target enrollmentApril 10, 2012

Overview

Phase
Phase 2
Intervention
Ibuprofen/acetaminophen
Conditions
Pain
Sponsor
Pfizer
Enrollment
394
Locations
1
Primary Endpoint
Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will determine the overall analgesic efficacy of three different fixed dose ibuprofen plus acetaminophen formulations compared to ibuprofen alone and to placebo.

Registry
clinicaltrials.gov
Start Date
April 10, 2012
End Date
September 13, 2012
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pfizer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females 16 to 40 years of age
  • Moderate to severe post-operative pain following surgical extraction of three or more third molar teeth

Exclusion Criteria

  • Presence of history of significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic or metabolic disorder
  • Pregnant or breastfeeding females

Arms & Interventions

Ibuprofen/acetaminophen (lower dose)

Intervention: Ibuprofen/acetaminophen

Ibuprofen/acetaminophen (middle dose)

Intervention: Ibuprofen/acetaminophen

Ibuprofen/acetaminophen (high dose)

Intervention: Ibuprofen/acetaminophen

Ibuprofen

Intervention: Ibuprofen

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8)

Time Frame: From 0 hour up to 8 hours post-dose

SPRID4:Time-weighted sum of pain relief rating (PRR) and pain intensity difference (PID) based on 4 point categorical severity rating scale (PRID) over 8 hours.SPRID 0-8 score range:-8 (worst score) to 56 (best score).PRID: sum of PRR and PID at each time point.PRID score range:-1= worst score to 7= best score.PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).PRR assessed on 5-point categorical scale with range:0 =no relief to 4 =complete relief.

Secondary Outcomes

  • Pain Intensity Difference on 4-Point Categorical Scale (PID4)(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Pain Intensity Difference on 11-Point Numerical Scale (PID11)(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Cumulative Percentage of Participants With Treatment Failure(1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Time to Confirmed First Perceptible Relief(From 0 hour up to 12 hours post-dose)
  • Pain Relief Rating Score (PRR)(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (SPRID4) Over 2, 6 and 12 Hours Post Dose(0 to 2 hours, 0 to 6 hours, 0 to 12 hours post-dose)
  • Cumulative Percentage of Participants With Meaningful Relief(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Time-weighted Sum of Pain Relief Rating (TOTPAR) Over 2, 6, 8, 12 Hours Post-Dose(0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose)
  • Time to Onset of Meaningful Pain Relief(From 0 hour up to 12 hours post-dose)
  • Time-weighted Sum of Pain Intensity Difference on 4-Point Categorical Scale (SPID4) Over 2, 6, 8 and 12 Hours Post-Dose(0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose)
  • Time-weighted Sum of Pain Intensity Difference on 11-Point Numerical Scale (SPID11) Over 2, 6, 8 and 12 Hours Post-Dose(0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose)
  • Cumulative Percentage of Participants With Confirmed First Perceptible Relief(0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose)
  • Time to Treatment Failure(From 0 hour up to 12 hours post-dose)
  • Participant Global Evaluation of Study Medication(12 hour)

Study Sites (1)

Loading locations...

Similar Trials